To confirm the clinical relevance of this finding, we extracted 740 lung adenocarcinoma from TCGA database, among which 54 patients were confirmed with EGFR activating mutation (n = 25), FGFR1/2 amplification (n = 15), MET amplification (n = 12), or RET fusion (n = 2). This evidence concerns the gene RET and lung adenocarcinoma.